Novartis' $12 Billion Bet Pays Off With Encouraging Data From Rare Neuromuscular Disease Study

기사 요약

Novartis reports positive Phase 1/2 del-brax data in FSHD, supporting Phase 3 development of a potential disease-modifying therapy.